If approved, MCO-010 would be the first treatment to restore vision in legally blind RP patients without needing genetic ...

AAVantgarde is now initiating ‘CELESTE’, a first-in-human Phase 1/2 clinical trial in the United States, to evaluate the safety, tolerability, and initial efficacy of AAVB-039 in patients with ...

Female sex hormones can significantly enhance the progression of the rare neurodegenerative eye disease retinitis pigmentosa (RP), according to a preclinical study by researchers at UT Southwestern ...

Beacon Therapeutics has completed the enrolment in its randomised, registrational Phase II/III VISTA trial of laru-zova.

Newer techniques using nanoparticles are less invasive, but some need bright visible light, which can harm any remaining ...

Microphthalmia, Anophthalmia & Coloboma Support (MACS) provides support to families of people born with Microphthalmia (small ...

Scientists at the Jules Stein Eye Institute at the David Geffen School of Medicine at UCLA have discovered that certain ...

New research shows that retinal neurons can rewire to preserve vision in retinitis pigmentosa, a genetic disease causing blindness.

Scientists at the Jules Stein Eye Institute at the David Geffen School of Medicine at UCLA have discovered that certain ...

There is a lot of talk at the moment about fears of World War 3 breaking out and conscription being introduced. And while it ...

Drivers must inform the DVLA of any condition that affects both eyes or one eye if the driver only has vision in one of them ...

The global retinitis pigmentosa market, valued at $11.31 billion in 2024, is expected to grow to $25.87 billion by 2034, driven by gene therapy advancements, aging populations, and strategic ...